HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO)

Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing--but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month's leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?"

STOMACH CANCER - THE LATEST TARGET FOR THE 'MAGIC BULLET'

Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years--imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously".
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
30-Oct-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Infectious Diseases (TLID)
5. The Lancet Neurology November press release
6. Lancet readers to join WHO election debate
7. The Lancet Oncology press release
8. The Lancet Neurology October press release
9. The Lancet neurology press release
10. The Lancet Neurology press release
11. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... , ... April 29, 2016 , ... In an ... and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent in ... youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s ...
(Date:4/29/2016)... ... 29, 2016 , ... Shamangelic Healing, Sedona Arizona's Premier ... Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness to ... the store is just one more way Shamangelic Healing supports people’s quest for ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the heart of our nation’s productivity, stability, even security. Most importantly, employees are ... organizations. , Then why are American workers so unhappy? , Just under half ...
(Date:4/29/2016)... ... , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite ... a light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers ... and 1-mile walk were held to increase awareness about Lyme disease and to ...
(Date:4/29/2016)... Texas (PRWEB) , ... April 29, 2016 , ... Spine ... neck pain, is proud to announce one of their physicians has been invited to ... Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
Cached News: